Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors.

McFall T, Stites EC.

Mol Cell Oncol. 2020 Jan 15;7(2):1701914. doi: 10.1080/23723556.2019.1701914. eCollection 2020.

PMID:
32158916
2.

A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.

McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC.

Sci Signal. 2019 Sep 24;12(600). pii: eaaw8288. doi: 10.1126/scisignal.aaw8288.

3.

Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor.

Erickson KE, Rukhlenko OS, Shahinuzzaman M, Slavkova KP, Lin YT, Suderman R, Stites EC, Anghel M, Posner RG, Barua D, Kholodenko BN, Hlavacek WS.

PLoS Comput Biol. 2019 Jan 17;15(1):e1006706. doi: 10.1371/journal.pcbi.1006706. eCollection 2019 Jan.

4.

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.

Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F.

Am J Med Genet A. 2018 Dec;176(12):2924-2929. doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10.

5.

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.

Stites EC, Shaw AS.

CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):342-351. doi: 10.1002/psp4.12291. Epub 2018 Mar 25.

6.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT.

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

7.

Use of mechanistic models to integrate and analyze multiple proteomic datasets.

Stites EC, Aziz M, Creamer MS, Von Hoff DD, Posner RG, Hlavacek WS.

Biophys J. 2015 Apr 7;108(7):1819-1829. doi: 10.1016/j.bpj.2015.02.030.

8.

Cooperation between Noncanonical Ras Network Mutations.

Stites EC, Trampont PC, Haney LB, Walk SF, Ravichandran KS.

Cell Rep. 2015 Feb 10;10(5):840. doi: 10.1016/j.celrep.2015.01.048. Epub 2015 Feb 11. No abstract available.

9.

Cooperation between Noncanonical Ras Network Mutations.

Stites EC, Trampont PC, Haney LB, Walk SF, Ravichandran KS.

Cell Rep. 2015 Jan 20;10(3):307-316. doi: 10.1016/j.celrep.2014.12.035. Epub 2015 Jan 15. Erratum in: Cell Rep. 2015 Feb 10;10(5):840.

10.

Allosteric activation of functionally asymmetric RAF kinase dimers.

Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS.

Cell. 2013 Aug 29;154(5):1036-1046. doi: 10.1016/j.cell.2013.07.046.

11.

Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine.

Stites EC.

Phys Biol. 2013 Apr;10(2):026004. doi: 10.1088/1478-3975/10/2/026004. Epub 2013 Feb 13.

PMID:
23406820
12.

Mathematical investigation of how oncogenic ras mutants promote ras signaling.

Stites EC, Ravichandran KS.

Methods Mol Biol. 2012;880:69-85. doi: 10.1007/978-1-61779-833-7_5. Review.

PMID:
23361982
13.

The response of cancers to BRAF inhibition underscores the importance of cancer systems biology.

Stites EC.

Sci Signal. 2012 Oct 16;5(246):pe46. doi: 10.1126/scisignal.2003354.

PMID:
23074264
14.

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D.

PLoS One. 2012;7(10):e43192. doi: 10.1371/journal.pone.0043192. Epub 2012 Oct 10.

15.

Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling.

Creamer MS, Stites EC, Aziz M, Cahill JA, Tan CW, Berens ME, Han H, Bussey KJ, Von Hoff DD, Hlavacek WS, Posner RG.

BMC Syst Biol. 2012 Aug 22;6:107. doi: 10.1186/1752-0509-6-107.

16.

Mechanistic modeling to investigate signaling by oncogenic Ras mutants.

Stites EC, Ravichandran KS.

Wiley Interdiscip Rev Syst Biol Med. 2012 Jan-Feb;4(1):117-27. doi: 10.1002/wsbm.156. Epub 2011 Jul 15.

PMID:
21766467
17.

Modeling membrane localization: case study of a Ras signaling model.

Stites EC.

Adv Exp Med Biol. 2010;680:661-7. doi: 10.1007/978-1-4419-5913-3_73.

PMID:
20865552
18.

A systems perspective of ras signaling in cancer.

Stites EC, Ravichandran KS.

Clin Cancer Res. 2009 Mar 1;15(5):1510-3. doi: 10.1158/1078-0432.CCR-08-2753. Epub 2009 Feb 10. Review.

19.

Network analysis of oncogenic Ras activation in cancer.

Stites EC, Trampont PC, Ma Z, Ravichandran KS.

Science. 2007 Oct 19;318(5849):463-7.

20.

Supplemental Content

Loading ...
Support Center